ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

FUM Futura Medical Plc

33.825
0.225 (0.67%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.225 0.67% 33.825 33.50 34.15 35.95 33.50 35.00 494,358 16:35:20
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 3.1M -6.51M -0.0216 -15.51 101.29M
Futura Medical Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 33.60p. Over the last year, Futura Medical shares have traded in a share price range of 24.10p to 57.00p.

Futura Medical currently has 301,449,541 shares in issue. The market capitalisation of Futura Medical is £101.29 million. Futura Medical has a price to earnings ratio (PE ratio) of -15.51.

Futura Medical Share Discussion Threads

Showing 15126 to 15139 of 21825 messages
Chat Pages: Latest  609  608  607  606  605  604  603  602  601  600  599  598  Older
DateSubjectAuthorDiscuss
14/12/2022
10:58
https://www.sec.gov/Archives/edgar/data/1182129/000110465914066948/a14-21083_3ex99d1.htm ED patients in my practice are looking for a safe and effective treatment option that also works fast, said Wayne JG Hellstrom, M.D., FACS, Professor of Urology at Tulane University School of Medicine in New Orleans and primary investigator for the clinical trial. "In my opinion, STENDRA can be an appropriate and important treatment option because the clinical trial demonstrated that it provides a rapid onset of action in many men in as early as approximately 15 minutes'https://www.globenewswire.com/en/news-release/2022/04/19/2424598/0/en/Petros-Pharmaceuticals-Announces-Positive-Results-of-Over-the-Counter-OTC-Label-Comprehension-Study-for-Erectile-Dysfunction-Drug-STENDRA-avanafil.html
lbo
14/12/2022
10:57
Interesting as now the co is in play for the massive US market.


This will filter back to the share price as potential commercial partners line up and news leaks


121p latest price target and that will be one tenth of what it will be worth if they even manage a 5% market share of a $5 billion pa market place

j777j
14/12/2022
10:48
LBO still filtered. Ho ho ho merry xmas.
joestalin
14/12/2022
10:48
How's that stock bashing going today, LiarBO? Hahaha!
petroc
14/12/2022
10:29
Someone ought to tell dreamer truant2tb1 that 'Higher this goes the more money i'll make on my short.' is not how it works. Hahahaha!
petroc
14/12/2022
10:26
All hell will break loose on FDA approval expected by March 2023 but your imaginary short will be making you money🤔
sos100
14/12/2022
10:24
Higher this goes the more money i'll make on my short. Watching and waiting...

RUG PULL in early 2023 + discounted placing

truant2tb1
14/12/2022
10:09
Pumpty dumpty sat on a wall! ROFLMAO
lbo
14/12/2022
10:08
No need to say anything to LiarBO today - except bwahahahahahahahahahaha! (And to endorse Losses' comment above! LiarBO will be crying to his mates the mods so that comment will soon be gone!) (Even though he is a lying ....)
petroc
14/12/2022
10:06
Perhaps expect a tree shake before the march continues.

Whatever happens well done all investors....a great couple of weeks performance from our FUM shares.

broomrigg
14/12/2022
09:49
Seems they are now admitting on the Futura website they will need more studies! Yet Trinity Research are saying Futura will still be loss making in 2023 and effectively run out of cash in 2023.

What if MED3000 is used in combination with PDE5is? Will post-approval studies be necessary?


We have not conducted studies on MED3000 in combination with PDE5i’s and it is not included on our proposed label. It is likely that a post-approval study will be needed to demonstrate synergy.

lbo
14/12/2022
09:40
The usual Pump and dump before yet another fundraising! or someone getting cheap shares for a convertible loan again? LOL

How else can they keep paying all those salaries, bonuses and free options.

lbo
14/12/2022
09:40
LBO shafted again
losses
14/12/2022
09:01
BLUE START.....persistant buying at these levels......60p by New Year?This is our 12th CONSECUTIVE BLUE DAY.Nice.
broomrigg
Chat Pages: Latest  609  608  607  606  605  604  603  602  601  600  599  598  Older

Your Recent History

Delayed Upgrade Clock